2014's Better Buy: Johnson & Johnson vs. Abbott Laboratories

Few stocks in health care are as recognizable as power players Johnson & Johnson and Abbott Labs . Both diversified health-care firms have broad reaches across several industries in the health sector, and both have been reliable stocks for investors for decades. But which stock is on track to perform the best for your portfolio in 2014?

Johnson & Johnson's fresh off of its fourth-quarter earnings report, in which the company's standout pharmaceutical division continued to see sales surge. However, J&J's outlook instilled worry among some industry analysts, sending the stock down despite an earnings beat. Meanwhile, while Abbott saw its big growth driver, its nutritionals division, sag in its own earnings report, the company still has a big presence overseas in emerging markets it hopes to capitalize on this year.

Does that make Abbott the stock you should believe in, or is Johnson & Johnson's surging drug unit too tempting to pass up? Find out in the video below, where Motley Fool contributor Dan Carroll compares these two stocks in the wake of their earnings announcements and shows you which is on the better track to reward your financial foundation this year.

Is your financial future looking safe?
Abbott and Johnson & Johnson have rewarded investors handsomely over the years as safe, strong stocks, but millions of Americans have waited on the sidelines since the market meltdown in 2008 and 2009, too scared to invest and put their money at further risk. Yet those who've stayed out of the market have missed out on huge gains and put their financial futures in jeopardy. In our brand-new special report, "Your Essential Guide to Start Investing Today," The Motley Fool's personal finance experts show you why investing is so important and what you need to do to get started. Click here to get your copy today -- it's absolutely free.

The article 2014's Better Buy: Johnson & Johnson vs. Abbott Laboratories originally appeared on Fool.com.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story